达雷妥尤单抗在多发性骨髓瘤中的应用

Application of daratumumab in multiple myeloma

达雷妥尤单抗是一种新型人源化抗CD38单克隆抗体,可靶向治疗多发性骨髓瘤(multiple myeloma,MM)瘤细胞表面的CD38,直接杀伤肿瘤细胞和通过调节免疫微环境双重作用机制发挥抗骨髓瘤作用。多项大型临床证实含达雷妥尤单抗联合方案不仅可用于新诊断MM患者的诱导、巩固治疗,也可作为复发/难治性MM患者的治疗选择,并在维持治疗阶段显示出良好的疗效与耐受性。真实世界研究进一步验证含达雷妥尤单抗的方案在MM患者中的疗效。文章基于已有的循证医学证据,重点介绍达雷妥尤单抗在MM中的临床应用。

Daratumumab,which is a new human monoclonal antibody used to treat multiple myeloma(MM)that targets CD38,has direct antitumor and immunomodulatory activity.Recent research has found that daratumumab-based regimens are widely used in the treatment of MM.The results of several large clinical trials have confirmed the clinical benefits of daratumumab in combination with other drugs.It can be used not only for induction and consolidation therapy in newly diagnosed MM but also as a treatment option for relapsed/refractory MM,and showing potential efficacy and tolerability in long-term maintenance therapy.The data of real-world research further support the improved survival of daratumumab-based regimens in MM.This article reviews the application of daratumumab in MM based on evidence-based research.